Australian company, AorTech Biomaterials Pty Ltd manufactures highly stable, highly biocompatible polymeric materials that are used in the medical device, pharmaceutical and biotechnology industries.
The company is listed on the UK AIM share market, with all research and development taking place in Australia. AorTech was founded to commercialise an exclusive worldwide licence obtained from the Cooperative Research Centre for Cardiac Technology to exploit Elast-Eon™, a novel biocompatible polymer developed by CSIRO’s Division of Molecular Science researchers working in the CRC. These materials are employed in the fields of cardiovascular, interventional cardiology, cardiac rhythm management and orthopaedics. The Elast-Eon™ surface features are engineered at the nanometre scale to result in a material that has minimal tissue adhesion, an essential attribute of its biocompatibility.
Aortech is embarking on a project focusing on nanoscale surface interaction properties of polymers to create bioactive surfaces that work with the body’s chemistry to promote healing. AorTech works with commercial partners, tailoring formulations to the specifications of medical device manufacturers, or developing new materials, processes and prototypes for use in specific applications, such as heart valves and breast implants, and has 17 projects underway.
Bio-polymers, Medical Grade Polyurethanes, Medical Implants, Cardiovascular Surgery, Interventional Cardiology, Cardiac Rhythm Management, Drug Delivery, Orthopaedic, Plastic Surgery,